Integrated Filing — IndAS



General information about company
Scrip Code 539523
NSE Symbol ALKEM
MSEI Symbol NOTLISTED
ISIN INE540L01014
Name of company ALKEM LABORATORIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 12-Aug-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 04-Aug-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment The Company is exclusively engaged in pharmaceutical business
Start date and time of board meeting 12-Aug-2025   11:00:00
End date and time of board meeting 12-Aug-2025   13:25:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 33711400000
Other income 1364900000
Total income 35076300000
2 Expenses
(a) Cost of materials consumed 8271100000
(b) Purchases of stock-in-trade 3972000000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -531500000
(d) Employee benefit expense 6932500000
(e) Finance costs 297800000
(f) Depreciation, depletion and amortisation expense 876800000
(f) Other Expenses
1 Other Expenses 7676800000 7676800000
Total other expenses 7676800000
Total expenses 27495500000
3 Total profit before exceptional items and tax 7580800000
4 Exceptional items 129300000
5 Total profit before tax 7710100000
6 Tax expense
7 Current tax 1411100000
8 Deferred tax -384200000
9 Total tax expenses 1026900000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations 6683200000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method -4100000
16 Total profit (loss) for period 6679100000
17 Other comprehensive income net of taxes 20800000
18 Total Comprehensive Income for the period 6699900000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 6642600000
Total profit or loss, attributable to non-controlling interests 36500000
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 23100000
Total comprehensive income for the period attributable to owners of parent non-controlling interests -2300000
21 Details of equity share capital
Paid-up equity share capital 239100000
Face value of equity share capital 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 55.56
Diluted earnings (loss) per share from continuing operations 55.56
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 55.56
Diluted earnings (loss) per share from continuing and discontinued operations 55.56
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) 1. The above consolidated financial results are prepared in accordance with the lndian Accounting Standards prescribed under section 133 of the Companies Act 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI LODR Regulations 2015. n n2. The above consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 11 August 2025 and subsequently approved by the Board of Directors at its meeting held on 12 August 2025. The auditors have issued an unmodified review report on the financial results for the quarter ended 30 June 2025. n n3.The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year. n n4.The comparative financial results of the Group for the quarter ended 30 June 2024 prepared in accordance with Ind AS included in this statement have been reviewed by the predecessor auditor. The report of the predecessor auditor on the comparative financial results is dated 9 August 2024. n n5.The Group has made the following acquisitions in wholly owned subsidiaries during the quarter ended 30 June 2025: na. 100% stake in Adroit Biomed Limited, on 23 April 2025 for a total consideration of Rs 1400 Million subject to conditions in the agreement. n nb. 100% stake in Bombay Ortho Industries Private Limited on 16 April 2025 through its wholly owned subsidiary Alkem Medtech Private Limited for a total consideration of Rs 1470 Million subject to conditions in the agreement. n nThe said acquisitions do not have any material impact on the results for the quarter ended 30 June 2025. n n6.Exceptional items for the quarter ended 30 June 2025 primarily includes: na. Gain of Rs 142.9 million from the sale of Indore facility classified as held for sale in the previous year and sold in the current period in accordance with the business transfer agreement entered with the buyer. n n7. The Group operates in one reportable business segment i.e. Pharmaceuticals, accordingly no separate disclosure of segment information has been made.



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurements of defined benefit plans -47600000 -47600000
Total Amount of items that will not be reclassified to profit and loss -47600000
2 Income tax relating to items that will not be reclassified to profit or loss -2900000
3 Amount of items that will be reclassified to profit and loss
1 Foreign currency translation difference of foreign operations 65500000 65500000
Total Amount of items that will be reclassified to profit and loss 65500000
4 Income tax relating to items that will be reclassified to profit or loss 0
5 Total Other comprehensive income 20800000